Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovascular risk profile in women with polycystic ovary syndrome or ovulatory hyperandrogenism: metformin versus oral contraceptive plus spironolactone
2008-004531-38Phase 3Active
- Sponsor
- Héctor Escobar-Morreale
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of metformin, desogestrel, ethinyl estradiol and spironolactone in polycystic ovary syndrome (PCOS) and Androgenization (2 arms), sponsored by Héctor Escobar-Morreale. Started Sep 2008; status: active.
02
Drugs
metformindesogestrelethinyl estradiolspironolactone
03
Conditions
polycystic ovary syndrome (PCOS)Androgenization
Beyond the preview
Go deeper on 2008-004531-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004531-38.